The Importance of Periodic Replacement of Influenza Vaccine Viruses – Medriva

The Importance of Periodic Replacement of Influenza Vaccine Viruses

Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. To protect against this disease, vaccines are regularly updated due to the continuous evolution of influenza viruses. The World Health Organization (WHO) and other health agencies monitor these changes and make recommendations for the composition of influenza vaccines, ensuring their effectiveness against the most recent strains.

As part of its mandate, the WHO conducts biannual consultations with an advisory group of experts to analyze surveillance data on influenza virus evolution. These experts then issue recommendations for the composition of influenza vaccines for the upcoming flu season. For instance, the WHO consultation for the 2024-2025 Northern Hemisphere influenza season will provide crucial guidance for the development, production, and licensing of influenza vaccines by national regulatory agencies and pharmaceutical companies. These consultations serve as an essential step in maintaining the ongoing effectiveness of influenza vaccines.

The Centers for Disease Control and Prevention (CDC) in the United States utilizes three key indicators to assess the severity of each flu season: influenza-like illness (ILI) outpatient visits, flu-related hospitalizations, and flu deaths. The severity classification can range from low to very high based on the highest weekly values observed for each indicator. The data sources for this assessment include the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Influenza Hospitalization Surveillance Network (FluSurv-NET), and National Center for Health Statistics (NCHS) Mortality Surveillance Data. These assessments can change as the season progresses, thus highlighting the necessity of timely and effective vaccination.

The European Centre for Disease Prevention and Control (ECDC) has developed a core protocol for studies of COVID-19 and influenza vaccine effectiveness. This protocol, built upon lessons learned from the ECDC-funded I-MOVE Influenza Monitoring Vaccine Effectiveness in Europe project, aims to provide more statistical power by combining data from multiple sites. The proposed method is a case-control study using a test-negative design, with the study population consisting of individuals hospitalized with severe acute respiratory infection (SARI) symptoms and no contraindication for vaccination. These studies play a vital role in informing vaccine development and distribution strategies.

The CDC also provides a Weekly Influenza Vaccination Dashboard that offers preliminary weekly flu vaccination data. This dashboard contains data on vaccine doses distributed, coverage for various demographics, and vaccination rates among specific populations like healthcare personnel. The information provided by this dashboard is critical in understanding the reach and effectiveness of influenza vaccination efforts, emphasizing the importance of flu vaccination for everyone six months and older, especially those at higher risk of serious complications from influenza.

The periodic replacement of influenza vaccine viruses is essential in ensuring the ongoing effectiveness of vaccines against this ever-evolving disease. Through rigorous surveillance, analysis, and consultation, health organizations worldwide continue to work together to protect global health against the threat of influenza. The collaborative efforts in monitoring influenza virus evolution, assessing flu season severity, studying vaccine effectiveness, and tracking vaccination coverage are fundamental components of this crucial health initiative.

Follow this link:

The Importance of Periodic Replacement of Influenza Vaccine Viruses - Medriva